CompletedNot Applicable

Soluble Triggering Receptor Expressed on Myeloid Cells in Severe Acute Pancreatitis

China30 participantsStarted 2008-07

Plain-language summary

Early diagnosis of secondary infection of necrotic tissue in severe acute pancreatitis is extremely important. The investigators evaluated whether the level of soluble TREM-1 (sTREM-1) in fine needle aspiration (FNA) fluid from patients who suspected infection is a good marker of secondary infection of necrotic tissue and an indicator of the proper treatment between drainage and necrosectomy.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18 years of age or older * Diagnosis of severe pancreatitis * Pancreatic or peripancreatic necrosis * Body temperature at least 38.3°C * Leukocytosis (more than 10,000 leukocytes per cubic millimeter) or leukopenia (fewer than 4000 leukocytes per cubic millimeter) Exclusion Criteria: * A flare-up of chronic pancreatitis * End-stage chronic diseases (including pancreatic and bile duct cancer) * Previous drainage or surgery for confirmed or suspected infected necrosis * An acute intraabdominal event (e.g., perforation of a visceral organ, bleeding, or the abdominal compartment syndrome)

What they're measuring

The level of sTREM-1 in fine needle aspiration fluid

Timeframe: more than 14 days after entry

Trial details

NCT IDNCT01193413

SponsorChanghai Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2009-07

View on ClinicalTrials.gov More Acute trials